Ativan is the brand name for lorazepam, a benzodiazepine prescribed for anxiety, seizure emergencies, and short term sedation. Employers and testing coordinators often assume any benzodiazepine drug on a standard test panel will flag automatically. With lorazepam, that assumption is not reliable. Because of how the body processes lorazepam, it is one of the more likely benzodiazepines to produce a false negative on a rapid immunoassay screen, even when a person has taken a normal, recently prescribed dose. This article explains the pharmacology behind that gap, where lorazepam sits in federal drug scheduling, whether it appears on the federal DOT panel, and how the confirmation and medical review officer (MRO) process is supposed to work.
What Ativan Is and How the Body Clears It
Lorazepam is a Schedule IV controlled substance under the Drug Enforcement Administration's controlled substances schedule list, the same schedule that covers most prescription benzodiazepines. According to the drug label on file with the National Library of Medicine, Ativan is indicated for the management of anxiety disorders and for the short term relief of anxiety symptoms, and it also has uses in status epilepticus and pre-procedure sedation under a clinician's direction. See the DailyMed label for Ativan (lorazepam) tablets for the full prescribing information.
The detail that matters most for testing is metabolism. Most benzodiazepines pass through the liver's cytochrome P450 pathway before they are conjugated and excreted. Lorazepam skips that first step. It is glucuronidated directly and excreted from the body almost entirely as lorazepam glucuronide, an inactive metabolite, rather than as a parent drug that behaves like the calibrators used in many screening assays. The NCBI Bookshelf clinical reference on lorazepam describes this pathway and notes an elimination half-life of roughly 14 hours, which is shorter than several other benzodiazepines. See StatPearls, Lorazepam for the pharmacology summary.
Why Lorazepam Can Cause a False Negative on a Screening Test
Standard benzodiazepine (BZO) immunoassay cups and dip cards, including most FDA cleared rapid tests, are built around antibodies that bind well to certain parent benzodiazepines and their common metabolites, such as oxazepam and nordiazepam pathways shared by diazepam type drugs. Lorazepam glucuronide does not bind those antibodies nearly as well. A peer reviewed comparison of clinical benzodiazepine immunoassays published through PubMed Central states plainly that benzodiazepines excreted primarily as glucuronidated metabolites, lorazepam among them, cross react poorly with FDA cleared immunoassays, which leads to false negative screening results even in specimens that later confirm positive by mass spectrometry. The same study found that switching to a laboratory developed test with an added glucuronidase hydrolysis step, which breaks the glucuronide bond before the antibody reaction, produced a large increase in confirmed lorazepam detections compared with the standard commercial assay. Read the full study at PubMed Central, benzodiazepine immunoassay comparison.
In practical terms, this means a rapid cup or dip card can come back negative for a person who is taking lorazepam exactly as prescribed, simply because the screening antibody was not built to catch the glucuronide form efficiently. It also means a low positive result should never be assumed to reflect the full picture, since sensitivity varies by manufacturer and by whether a hydrolysis step is used.
| Factor | What typically applies |
|---|---|
| Drug class tested | Benzodiazepine (BZO) panel, an add on to standard 5 or 10 panel urine and oral fluid tests |
| Primary urinary form | Lorazepam glucuronide (inactive metabolite), not much free parent drug |
| Screening risk | Higher chance of a false negative on standard immunoassays without a glucuronidase hydrolysis step |
| Confirmation method | Gas or liquid chromatography with mass spectrometry (GC/MS or LC/MS/MS) at a certified lab |
| DOT federal panel | Not included; DOT testing under 49 CFR Part 40 does not screen for benzodiazepines |
| DEA schedule | Schedule IV |
Is Ativan on the DOT Drug Test Panel?
No. The federally mandated drug panel for safety sensitive transportation employees under 49 CFR Part 40 covers marijuana metabolites, cocaine metabolites, opioids (codeine, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and 6 acetylmorphine), phencyclidine, and amphetamines including MDMA and MDA. Benzodiazepines such as lorazepam are not part of that cutoff table. The full regulatory cutoff list is published by the Government Publishing Office; see 49 CFR Part 40, subpart E test cutoffs (govinfo.gov). A non-DOT employer can still choose to add a BZO panel to a private testing program, but that is a separate, employer selected panel, not a federal requirement.
What Happens When a Benzodiazepine Screen Is Positive
A positive screening result on a BZO panel is not a final result. It is a presumptive finding that must go to confirmation testing by chromatography and mass spectrometry, which identifies the specific compound and quantity rather than reacting to a class of drugs the way an immunoassay does. In a regulated DOT testing program, a certified laboratory reports a confirmed positive to a medical review officer, a licensed physician trained in substance abuse testing, who contacts the employee to ask about current, legally valid prescriptions before any result is reported to the employer. If a verified prescription explains the result, the MRO generally reports the test as negative or as a legitimate medical explanation rather than a verified positive. For non-DOT programs, employers should build an equivalent MRO or medical review step into their own policy documentation, since state law and program design vary. General MRO verification procedures are set out in 49 CFR Part 40 subpart G, available in the same 49 CFR Part 40 text (govinfo.gov).
Employers should never treat a screening level result as proof of anything on its own, and should route every non-negative BZO result through confirmation and MRO review before taking any employment action. Because lorazepam is a Schedule IV controlled substance, an employee with a current, valid prescription is not doing anything unlawful by taking it as directed. The question for an employer is generally about fitness for duty and safety, not about the prescription itself, and that determination may benefit from legal counsel given how ADA and state disability accommodation rules interact with prescribed medication.
Not Every Benzodiazepine Behaves the Same Way
Employers sometimes assume the BZO panel is a single reliable test for the whole drug class, but the class is chemically diverse. Some benzodiazepines, such as diazepam, metabolize into intermediate compounds like nordiazepam and oxazepam that standard immunoassays were originally designed to detect, so they tend to screen positive more consistently. Lorazepam, oxazepam, and temazepam instead undergo direct glucuronidation, skipping that intermediate step entirely, which is the specific reason the peer reviewed comparison cited above singles them out as the group most prone to false negative screening results. Practically, this means a panel that reliably catches one benzodiazepine prescription can still miss another, and program administrators should not assume uniform sensitivity across every drug the BZO panel is marketed to cover.
Urine Versus Oral Fluid Considerations
Employers choosing between urine and oral fluid collection for a program that includes a benzodiazepine analyte should know that federal cutoff concentrations differ by specimen type and are set out separately in 49 CFR Part 40, with urine cutoffs addressed in subpart E and oral fluid cutoffs addressed in a later subpart of the same rule. Because oral fluid testing reflects a shorter window of recent use and a different collection method than urine, sensitivity to a specific metabolite such as lorazepam glucuronide can vary by specimen type and by the assay a given laboratory has validated, not just by the drug itself. Programs that need consistent benzodiazepine detection should confirm with their laboratory which specimen type and assay configuration was validated for glucuronidated metabolites before assuming either method performs the same way.
What This Means for Testing Programs
Programs that rely only on a standard immunoassay BZO cup should understand that a negative result does not rule out recent lorazepam use, and a positive result on any panel always requires laboratory confirmation before it means anything. Facilities that need higher sensitivity to glucuronidated benzodiazepines typically send specimens to a laboratory that either uses an assay validated for glucuronide metabolites or performs confirmation testing as a matter of course on all non-negatives, rather than relying on rapid onsite results alone for any employment decision. Documenting the assay's known limitations in a written testing policy also helps an employer respond consistently if an employee later raises a valid prescription during the MRO review process.
Frequently asked questions
Does Ativan show up on a standard 5 panel drug test?
A standard federal 5 panel test does not include a benzodiazepine analyte, so Ativan (lorazepam) would not be targeted unless a BZO panel is specifically added to the test.
Can a prescription for lorazepam cause a failed drug test?
A confirmed positive benzodiazepine result with a current, valid prescription is generally documented as a legitimate medical explanation once verified by a medical review officer, rather than treated as illicit use.
Why would a drug test miss Ativan even though the person took it recently?
Lorazepam is excreted mostly as lorazepam glucuronide, and many standard immunoassay screens cross react poorly with that metabolite, which can produce a false negative even at a therapeutic dose.
Is lorazepam tested for on a DOT drug test?
No. The federal DOT panel under 49 CFR Part 40 covers marijuana, cocaine, opioids, PCP, and amphetamines. It does not include benzodiazepines.
How long can lorazepam be detected in urine?
Detection windows vary by dose, frequency of use, individual metabolism, and the sensitivity of the specific assay used, so there is no single fixed timeframe that applies to everyone.
What confirms a positive benzodiazepine screen?
Laboratories use gas or liquid chromatography combined with mass spectrometry to confirm and identify the specific benzodiazepine and its concentration after an initial screen is non-negative.
Related Reading
For a broader look at how the benzodiazepine class performs across different assay types, see our overview of the Benzodiazepine Drug Test: BZO Panel Detection Times and Gaps. For a comparison covering a different benzodiazepine with its own detection profile, see Does Klonopin Show Up on a Drug Test? Clonazepam and the Benzodiazepine Panel.
Employers building or refreshing a testing program can review our drug test cup collection for panel configurations, including options that add a BZO analyte to a standard multi drug panel.
This article is for general informational purposes only and is not legal or medical advice. Testing requirements, assay performance, and legal obligations vary by employer, state, and program; consult qualified legal counsel and your laboratory's medical review officer for guidance specific to your situation.
